Universal reference book for medicines
Name of the preparation: VACCINUM PAROTYTINA CULTURAL LIVING (VACCINUM PAROTITIDI CULTURARUM VIVUM)

Active substance: mumps vaccine (live)

Type: Vaccine for the prevention of measles and mumps

Producer: NGO MIKROGEN (Russia), a branch of the Moscow State Enterprise for the Production of Pharmaceutical Products (Russia)
Composition, form of production and packaging
Liofilizate for the preparation of a solution for administration of a
1 dose

mumps virus not less than 20 000 TCD 50

1 dose - ampoules (10) - packs of cardboard.

Liofilizate for the preparation of a solution for administration of a 1 dose

mumps virus not less than 20 000 TCD 50

2 doses - ampoules (10) - packs of cardboard.

Liofilizate for the preparation of a solution for administration of a 1 dose

mumps virus not less than 20 000 TCD 50

5 doses - ampoules (10) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2010.

PHARMACHOLOGIC EFFECT

The vaccine stimulates seronegative children to develop antibodies to the mumps virus, reaching a maximum level 6-7 weeks after vaccination.
The drug meets WHO requirements.
INDICATIONS

- prevention of mumps.

Routine vaccinations are carried out twice at the age of 12 months and 6 years for children who do not have mumps epidemic parotitis.

Emergency prophylaxis is administered to children from 12 months, adolescents and adults who have had contact with mumps, who have not had mumps or who have not previously been vaccinated against this infection.

In the absence of contraindications, the vaccine is administered no later than 72 hours after contact with the patient.

DOSING MODE

Immediately prior to use, the vaccine is diluted with diluent for measles, mumps and mumps in live culture vaccines (hereinafter referred to as the solvent) at a rate of 0.5 ml of solvent per vaccination dose of the vaccine.

The vaccine should completely dissolve within 3 minutes.
The dissolved vaccine is a transparent liquid of pink color.
Vaccine and solvent in ampoules with broken integrity, marking, as well as changing their physical properties (color, transparency, etc.), expired or incorrectly stored, are not suitable for use.

Opening of ampoules and the vaccination procedure are carried out with strict adherence to aseptic and antiseptic rules.

Ampoules with a vaccine and a solvent in place of the incision are treated with 70% alcohol and break off, while avoiding the ingress of alcohol into the ampoule.

To dilute the vaccine, take all the necessary volume of the solvent and transfer it to an ampoule with a dry vaccine.
After mixing, the vaccine is taken up by another needle in a sterile syringe and used for vaccination.
The vaccine is administered SC in a volume of 0.5 ml under the shoulder blade or in the shoulder region (on the border between the lower and middle third of the shoulder from the outside), after preliminary treatment of the skin at the site of administration of the vaccine with 70% alcohol.

The dissolved vaccine is used immediately and is not subject to storage.

Vaccination is recorded in the prescribed registration forms with the name of the drug, the date of vaccination, dose, manufacturer, serial number, expiration date, response to vaccination.

SIDE EFFECT

In most children, the vaccinal process is asymptomatic.
At a part of children can be observed:
- from 5 to 15 days - temperature reactions, catarrhal phenomena from the nasopharynx (hyperaemia, rhinitis);

- from 5 to 42 days - a slight increase in parotid salivary glands lasting 2-3 days;

- In rare cases, during the first 48 hours after vaccination, local reactions, expressed in skin hyperemia and mild edema at the site of administration of the vaccine, which go untreated.

In case of mass application of the vaccine, the increase in body temperature above 38.5 ° C should not be more than 2% of vaccinated children.

Complications that develop extremely rarely include allergic reactions that occur in the first 24-48 hours in children with altered reactivity.
It is extremely rare for vaccinated in 2-4 weeks to develop benign serocious meningitis. Every case of serous meningitis requires differential diagnosis.
A rise in body temperature above 38.5 ° C in the post-vaccination period is an indication for the administration of antipyretics.

CONTRAINDICATIONS

- severe forms of allergic reactions to aminoglycosides (gentamycin sulfate) and chicken eggs;

- primary immunodeficiency states, malignant blood diseases and neoplasms;

- a strong reaction (temperature rise above 40 ° C, hyperemia and / or swelling more than 8 cm in diameter at the site of administration of the vaccine) or complication of previous introduction of mumps or mumps in the vaccine;

- Pregnancy.

In order to identify contraindications, the doctor (paramedic) on the day of vaccination conducts a survey and examination of the vaccine with mandatory thermometry.
If necessary, conduct appropriate laboratory examination.
HIV infection is not a contraindication to vaccination.

Persons temporarily released from vaccinations should be monitored and recorded and vaccinated after withdrawal of contraindications.

PREGNANCY AND LACTATION

Contraindicated in pregnancy.

APPLICATION FOR CHILDREN

Apply on indications.

SPECIAL INSTRUCTIONS

Vaccinations are conducted:

- after acute infectious and non-infectious diseases, after exacerbation of chronic diseases - after the end of acute manifestations of the disease;

- with mild ARVI, acute intestinal diseases, etc. - immediately after the normalization of temperature;

- After immunosuppressive therapy, the inoculation is carried out 3-6 months after the end of treatment;

- Vaccination against mumps is not recommended during the period of rising incidence of serous meningitis.

DRUG INTERACTION

Vaccination against mumps can be performed simultaneously (on day 1) with other calendar vaccinations (against measles, rubella, poliomyelitis, hepatitis B, pertussis, diphtheria, tetanus) or not earlier than 1 month after the previous vaccination.

After the introduction of human immunoglobulin preparations, inoculations against mumps are carried out not earlier than in 2 months.
After the introduction of a mumps vaccine, immunoglobulin preparations can be administered no earlier than 2 weeks; If immunoglobulin is required before this time, vaccination against mumps should be repeated.
TERMS OF RELEASE FROM PHARMACY

For treatment and prevention institutions.

TERMS AND CONDITIONS OF STORAGE

The vaccine is stored and transported in accordance with SP 3.3.2.1248-03 at temperatures from 0 to 8 ° C in a place inaccessible to children.

Shelf life of the vaccine is 15 months.
The drug with expired shelf life is not subject to application.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!